Friday, BB Biotech AG (BBZA.DE) said based on preliminary and unaudited figures, that the company closed the 2025 financial year with a profit of about CHF 578 million, marking a sharp improvement from the CHF 76 million profit reported a year earlier.
The company said the result largely reflects share price movements across its investment portfolio, a key driver of performance for an investment-focused business such as BB Biotech.
Full portfolio details and the complete annual report are scheduled for release on February 20, 2026.
BBZA.DE currently trades at 53.2 euros or 0.19% higher on the XETRA.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.